inclusion criteria: 1. voluntary signature of the irb approved informed consent 2. at least 4-weeks post ventilator or oxygen dependent ards treated for at least 48 hours in the icu 3. patient is stable enough to have been discharged home 4. male or female ages 18-85 5. two weeks to 1-year post hospital discharge 6. ongoing activity intolerance due to dyspnea related to ards 7. is independent, ambulatory, and can comply with all post-operative evaluations and visits 8. 6-minute walk test distance of \< 450 m 9. sf-36 physical component score \< 60 10. ards caused by viral pneumonia including covid-19 confirmed through an rna anti-body test 11. normal to mild post-ards reactive airway disease

inclusion criteria: 1. voluntary signature of the irb approved informed consent 2. at least 4-weeks post ventilator or oxygen dependent ards treated for at least 48 hours in the icu 3. patient is stable enough to have been discharged home 4. male or female ages 18-85 5. two weeks to 1-year post hospital discharge 6. ongoing activity intolerance due to dyspnea related to ards 7. is independent, ambulatory, and can comply with all post-operative evaluations and visits 8. 6-minute walk test distance of \< 450 m 9. sf-36 physical component score \< 60 10. ards caused by viral pneumonia including covid-19 confirmed through an rna anti-body test 11. normal to mild post-ards reactive airway disease

inclusion criteria: voluntary signature of the irb approved informed consent at least 4-weeks post ventilator or oxygen dependent ards treated for at least 48 hours in the icu patient is stable enough to have been discharged home male or female ages 18-85 two weeks to 1-year post hospital discharge ongoing activity intolerance due to dyspnea related to ards is independent, ambulatory, and can comply with all post-operative evaluations and visits 6-minute walk test distance of < 450 m sf-36 physical component score < 60 ards caused by viral pneumonia including covid-19 confirmed through an rna anti-body test normal to mild post-ards reactive airway disease

inclusion criteria: voluntary signature of the irb approved informed consent at least 4-weeks post ventilator or oxygen dependent ards treated for at least 48 hours in the icu patient is stable enough to have been discharged home male or female ages 18-85 two weeks to 1-year post hospital discharge ongoing activity intolerance due to dyspnea related to ards is independent, ambulatory, and can comply with all post-operative evaluations and visits 6-minute walk test distance of < 450 m sf-36 physical component score < 60 ards caused by viral pneumonia including covid-19 confirmed through an rna anti-body test normal to mild post-ards reactive airway disease

inclusion criteria: 1. voluntary signature of the irb approved informed consent 2. at least 4-weeks post ventilator or oxygen dependent ards treated for at least 48 hours in the icu 3. patient is stable enough to have been discharged home 4. male or female ages 18-85 5. two weeks to 1-year post hospital discharge 6. ongoing activity intolerance due to dyspnea related to ards 7. is independent, ambulatory, and can comply with all post-operative evaluations and visits 8. 6-minute walk test distance of < 450 m 9. sf-36 physical component score < 60 10. ards caused by viral pneumonia including covid-19 confirmed through an rna anti-body test 11. normal to mild post-ards reactive airway disease

inclusion criteria: 1. voluntary signature of the irb approved informed consent 2. at least 4-weeks post ventilator or oxygen dependent ards treated for at least 48 hours in the icu 3. patient is stable enough to have been discharged home 4. male or female ages 18-85 5. two weeks to 1-year post hospital discharge 6. ongoing activity intolerance due to dyspnea related to ards 7. is independent, ambulatory, and can comply with all post-operative evaluations and visits 8. 6-minute walk test distance of < 450 m 9. sf-36 physical component score < 60 10. ards caused by viral pneumonia including covid-19 confirmed through an rna anti-body test 11. normal to mild post-ards reactive airway disease